This study will establish proof of principle for an innovative technique of ACL repair with a device made of collagen and autologous platelets which stimulates healing of the transacted ACL. The advantages over the current gold standard of treatment of ACL reconstruction are that it is minimally invasive, thus less traumatic to the knee, and it preserves the broad insertion sites and proprioceptive function of the native ACL. Preliminary studies with this device show excellent healing of the partial ACL tear in canines and early healing of ACL repair. The use of this technology will significantly reduce procedure time and rehabilitation time, eliminate complications and morbidity associated with graft harvesting, and dramatically cut the pain and lost productivity of reconstruction surgery. Preliminary estimates show that repair with our technology can save the U.S. health system over $1 billion in direct cost and substantially more in indirect costs by regaining thousands of person-years of lost productivity. A collagen-platelet composite has been developed and validated by the investigators in a canine model to heal partial ACL tears both biomechanically and histologically. The porcine model will allow evaluation for development of osteoarthritis (OA), repair strength, comparison of biomechanical results and histology to known standards, and has the potential to control rehabilitation in the future.